These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
892 related articles for article (PubMed ID: 32780660)
1. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660 [TBL] [Abstract][Full Text] [Related]
2. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657 [TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L). Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781 [TBL] [Abstract][Full Text] [Related]
4. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; Garcia Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira AI; Gettinger SN; Tiseo M; Lin HM; Liu Y; Vranceanu F; Niu H; Zhang P; Popat S J Thorac Oncol; 2021 Dec; 16(12):2091-2108. PubMed ID: 34537440 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. Ahn MJ; Kim HR; Yang JCH; Han JY; Li JY; Hochmair MJ; Chang GC; Delmonte A; Lee KH; Campelo RG; Gridelli C; Spira AI; Califano R; Griesinger F; Ghosh S; Felip E; Kim DW; Liu Y; Zhang P; Popat S; Camidge DR Clin Lung Cancer; 2022 Dec; 23(8):720-730. PubMed ID: 36038416 [TBL] [Abstract][Full Text] [Related]
6. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716 [TBL] [Abstract][Full Text] [Related]
7. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119 [TBL] [Abstract][Full Text] [Related]
8. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Popat S; Liu G; Lu S; Song G; Ma X; Yang JC Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676 [TBL] [Abstract][Full Text] [Related]
9. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Kim DW; Tiseo M; Ahn MJ; Reckamp KL; Hansen KH; Kim SW; Huber RM; West HL; Groen HJM; Hochmair MJ; Leighl NB; Gettinger SN; Langer CJ; Paz-Ares Rodríguez LG; Smit EF; Kim ES; Reichmann W; Haluska FG; Kerstein D; Camidge DR J Clin Oncol; 2017 Aug; 35(22):2490-2498. PubMed ID: 28475456 [TBL] [Abstract][Full Text] [Related]
10. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. Yang JC; Liu G; Lu S; He J; Burotto M; Ahn MJ; Kim DW; Liu X; Zhao Y; Vincent S; Yin J; Ma X; Lin HM; Popat S J Thorac Oncol; 2023 Dec; 18(12):1743-1755. PubMed ID: 37574132 [TBL] [Abstract][Full Text] [Related]
11. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. Naito T; Shiraishi H; Fujiwara Y Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606 [TBL] [Abstract][Full Text] [Related]
12. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE). Shi Y; Chen J; Yang R; Wu H; Wang Z; Yang W; Cui J; Zhang Y; Liu C; Cheng Y; Liu Y; Shan J; Wang D; Yang L; Hu C; Zhao J; Cao R; Tan B; Xu K; Si M; Li H; Mao R; Li L; Kang X; Wang L J Thorac Oncol; 2024 Jun; 19(6):912-927. PubMed ID: 38280448 [TBL] [Abstract][Full Text] [Related]
13. Brigatinib versus crizotinib for ALK-positive NSCLC. Stirrups R Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790 [No Abstract] [Full Text] [Related]
14. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676 [TBL] [Abstract][Full Text] [Related]
15. Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC. Hoy SM Drugs; 2021 Feb; 81(2):267-275. PubMed ID: 33528789 [TBL] [Abstract][Full Text] [Related]
16. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983 [TBL] [Abstract][Full Text] [Related]
17. Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial. Garcia Campelo MR; Wan Y; Lin HM; Chen T; Shen J; Zhang P; Camidge DR Lung Cancer; 2023 Nov; 185():107376. PubMed ID: 37722340 [TBL] [Abstract][Full Text] [Related]
18. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890 [TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective. Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099 [No Abstract] [Full Text] [Related]
20. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E; Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]